Regenerative medicine-focused Histogenics said Wednesday it signed a supply deal with U.K.-based Collagen Solutions.
Collagen Solutions will provide collagen material sources for use in Histogenics investigational NeoCart which is being designed to repair knee cartilage damage. The NeoCart product is currently in phase 3 trials.
“Collagen Solutions has again demonstrated that it can provide materials which add real value to the delivery of novel regenerative therapies such as NeoCart, which is a novel product that is synergistic with ChondroMimetic, the product which Collagen Solutions recently acquired. We are very pleased to be part of the Histogenics journey and look forward to participating in an exciting future with Adam and the team in Boston,” Collagen Solutions CEO Dr. Stewart White said in a press release.
The supply agreement could also cover future pipeline products for Waltham, Mass.-based Histogenics, the company said
“We are pleased to enter into this partnership with Collagen Solutions in the United Kingdom as they have the historical know-how, leading technical capabilities and unique technology platforms that will provide additional supply capabilities in the United States and potentially serve our future product development requirements for new indications and for our markets outside of the U.S. We have been looking for a collaboration partner for some time to augment our internal primary collagen supply chain capabilities for NeoCart, which remain on track. Stewart and the team at Collagen Solutions fit our criteria perfectly, and we look forward to building upon our partnership to potentially provide patients with exciting new biologic therapeutics for the treatment of cartilage defects,” Histogenics CEO Adam Gridley said in prepared remarks.